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Breathlessness during daily activity:  
The psychometric properties of the  
London Chest Activity of Daily Living  
Scale in patients with advanced disease  
and refractory breathlessness
Charles C Reilly1,2, Claudia Bausewein1,3, Rachel Garrod4, 
Caroline J Jolley5,6, John Moxham5 and Irene J Higginson1
Abstract
Background: The London Chest Activities of Daily Living Scale measures the impact of breathlessness on both activity and 
social functioning. However, the London Chest Activities of Daily Living Scale is not routinely used in patients with advanced 
disease.
Aim: To assess the psychometric properties of the London Chest Activities of Daily Living Scale in patients with refractory 
breathlessness due to advanced disease.
Design: A cross-sectional secondary analysis of data from a randomised controlled parallel-group, pragmatic, single-blind fast-track 
trial (randomised controlled trial) investigating the effectiveness of an integrated palliative and respiratory care service for patients 
with advanced disease and refractory breathlessness, known as the Breathlessness Support Service (NCT01165034). All patients 
completed the following questionnaires: the London Chest Activities of Daily Living Scale, Chronic Respiratory Questionnaire, the 
Palliative care Outcome Scale, Palliative care Outcome Scale–symptoms, the Hospital Anxiety and Depression Scale and breathlessness 
measured on a numerical rating scale. Data quality, scaling assumptions, acceptability, internal consistency and construct validity of the 
London Chest Activities of Daily Living Scale were determined using standard psychometric approaches.
Setting/participants: Breathless patients with advanced malignant and non-malignant disease.
Results: A total of 88 patients were studied, primary diagnosis included; chronic obstructive pulmonary disease = 53, interstitial 
lung disease = 17, cancer = 18. Median (range) London Chest Activities of Daily Living Scale total score was 46.5 (14–67). No floor 
or ceiling effect was observed for the London Chest Activities of Daily Living Scale total score. Internal consistency was good, and 
Cronbach’s alpha for the London Chest Activities of Daily Living Scale total score was 0.90. Construct validity was good with 13 
out of 15 a priori hypotheses met.
Conclusion: Psychometric analyses suggest that the London Chest Activities of Daily Living Scale is acceptable, reliable and valid in 
patients with advanced disease and refractory breathlessness.
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Introduction
Refractory breathlessness (RB) is defined as breathless-
ness at rest or on minimal exertion that will persist chron-
ically despite optimal treatment of the underlying 
cause(s).1 RB is a common and distressing symptom for 
people in advanced stages of disease. In particular, peo-
ple suffering from chronic respiratory diseases, cancer 
and heart failure report RB as a significant symptom 
towards the end of life.2–4
Recently, we found that an integrated palliative and 
respiratory care service for patients with advanced dis-
ease and RB, known as the Breathlessness Support 
Service (BSS), improved patients’ mastery over their 
breathlessness, with a survival benefit for those patients 
who had early access to the BSS.5 Key components to 
this complex intervention were physiotherapy and occu-
pational therapy, which were individually tailored to 
meet the needs of these patients and their carers, deliv-
ered in the patients’ home.5
There is increasing evidence to support the role and 
benefit of physiotherapy and occupational therapy for 
patients with breathlessness due to advanced disease.5,6 
Despite this, patients’ access to these services is often 
limited.
Failure to access therapy services in this patient popula-
tion may be due to the fact that clinical decisions including 
referrals to therapy services are often made on the basis of 
objective tests of lung function and changes thereof. 
Traditional measures of lung function such as spirometry 
are poorly correlated to breathlessness and functional 
impairment.7 Furthermore, there is a lack of patient-
reported outcome measures (PROMs) specific to breath-
lessness during activities of daily living (ADLs) in this 
patient population. Therefore, objective assessment of 
therapy need is difficult.
Potentially, the London Chest Activity of Daily Living 
Scale (LCADL) may be a useful PROM to assess the func-
tional impact of RB, which may facilitate referral to ther-
apy. The LCADL was developed by Garrod et al.8,9 to 
measure the impact of breathlessness on ADLs in patients 
with chronic obstructive pulmonary disease (COPD). The 
LCADL has been shown to be sensitive to change pre–post 
pulmonary rehabilitation in patients with COPD.9 However, 
the performance of the LCADL in RB is unknown. The pri-
mary aim of the study was to examine the psychometric 
properties of the LCADL in patients with advanced disease 
and RB. The secondary aim was to investigate if diagnosis 
or presence of a carer influenced LCADL scores.
Methods
Design
A cross-sectional secondary analysis of data from a ran-
domised controlled parallel-group, pragmatic, single-blind 
fast-track trial (randomised controlled trial) investigating 
the effectiveness of an integrated palliative and respiratory 
care service for patients with advanced disease and RB, 
known as the BSS.5 Ethics approval for the study was 
obtained from the King’s College Hospital ethics commit-
tee (Ref. 10/H0808/17). The study protocol is registered 
with ClinicalTrials.gov (NCT01165034). All patients 
entering the study gave informed written consent.
Patients
Breathless patients with advanced malignant and non-
malignant disease were studied. Patients were referred to 
the BSS by health care professionals in primary and 
What is already known about this topic?
•• Refractory breathlessness is common in advanced disease.
•• There is increasing evidence to support the role and benefit of physiotherapy and occupational therapy for patients with 
breathlessness due to advanced disease. Despite this, patients’ access to these services is often limited.
•• There is a lack of patient-reported outcome measures (PROMs) specific to breathlessness during activities of daily living 
(ADLs) in this patient population. Therefore, objective assessment of therapy need in this patient population is difficult.
What this paper adds?
•• This paper demonstrates that The London Chest Activities of Daily Living Scale (LCADL) questionnaire is acceptable, 
reliable and valid to assess the impact of refractory breathlessness on ADLs in patients with advanced disease.
•• This paper highlights the importance of asking context-specific questions regarding breathlessness during ADLs, which 
can facilitate onward therapy referrals/interventions.
Implications for practice, theory or policy
•• In clinical practice, the LCADL can be used as both a screening tool to identify therapy needs and assess the impact of 
therapeutic interventions.
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secondary care. Patients suffered from RB of any cause. 
Optimal medical management was ensured by the refer-
ring health care professionals and patients were considered 
appropriate for palliative support of breathlessness. These 
patients were all offered access to two outpatient appoint-
ments with respiratory and palliative medicine input, and a 
joint home visit by physiotherapy and occupational ther-
apy. Patients and carers also had access to a palliative care 
social worker.5
Assessments
Data were collected during face-to-face interviews with 
patients, usually within the patient’s own home prior to 
randomisation.5
Pulmonary function. Forced expiratory volume in 1 s 
(FEV1), slow vital capacity (VC) and peak expiratory flow 
rate (PEF) were measured in all patients in the seated, 
upright position using a portable electronic spirometer 
(Vitalograph 2120®; Vitalograph®, Buckingham, UK).10 
Pulse oximetry was measured at rest in all participants.
Breathlessness. A numerical rating scale (NRS) was used 
to assess the intensity of the sensation of breathlessness at 
rest and on exertion over the last 24 h.11
Symptom-related quality of life. Symptom-related quality of 
life (QOL) was assessed using the Palliative care Outcome 
Scale (POS) and POS–symptoms to quantify palliative 
care symptoms in addition to breathlessness. A high total 
POS score is indicative of the complexity of individual 
patient palliative care needs; however, careful review of 
each component part of the POS is required when planning 
and evaluating treatments and interventions.12
Activity of daily living assessment. The LCADL was used to 
assess the impact and severity of breathlessness on ADLs. 
The LCADL has been used as an outcome measure in 
COPD and heart failure, where it has been shown to be 
valid, reliable and responsive to change.8,9,13 Higher scores 
reflect greater breathlessness during daily activity and the 
tool includes an anchor question identifying an individu-
al’s overall perception of the impact of breathlessness on 
their daily life.
Health – status assessment. The Chronic Respiratory Ques-
tionnaire (CRQ) was used to measure health status and 
was designed for the assessment of change in individuals. 
It comprises four component scores: Dyspnoea, Fatigue, 
Emotional function and Mastery. The CRQ is a multidi-
mensional tool and is one of the most widely used meas-
ures of QOL in chronic respiratory disease. The CRQ is an 
interview-administered questionnaire, but a self-adminis-
tered version maintains validity and responsiveness.14,15
Anxiety and depression. The Hospital Anxiety and Depres-
sion Scale (HADS) was used to assess anxiety and depres-
sion and consists of 14 items and is scored from 0 to 21, 
with a score of greater than 10 in either anxiety or depres-
sion representing symptoms of clinical significance.16
Statistical analysis
Five psychometric qualities of the LCADL were evaluated 
according to standard methodology:17–19
1. Data quality was assessed by calculating the per-
centage of missing items (number of missing items/
total number of item response possible) for each 
scale. Open response text fields were not included.
2. Scaling assumptions were examined by calculating 
individual item median scores. Inter-item correla-
tions were calculated using Spearman’s correlation 
coefficients.
3. Acceptability was determined by analysing the dis-
tribution of patients’ total scores (median, range, 
interquartile range) and floor and ceiling effect if 
15% of respondents achieved the lowest or highest 
possible score, respectively.18
4. Internal consistency (reliability) of the LCADL was 
determined using Cronbach’s alpha coefficient. 
Internal consistency is valid only if all items form a 
unidimensional (sub) scale, and the set of items 
forms a reflective model (i.e. all items are expected 
to change when the construct changes).19 A 
Cronbach’s alpha between 0.70 and 0.95 indicates 
good internal consistency without homogeneity.18
5. Construct validity is the extent to which scores on 
an instrument relate to other measures. It is given a 
positive rating if at least 75% of the results are con-
sistent with predefined hypotheses.18 Construct 
validity of the LCADL was tested against items 
within CRQ, POS, POS-s, HADS and NRS breath-
lessness scores using Spearman’s correlation coef-
ficients, according to predefined hypotheses of 
convergent validity (moderate and weak) and 
divergent validity (hypotheses and their results 
shown in Table 3).19 We defined the strength of the 
correlation as strong (0.7–1.0), moderate (0.4–0.7), 
weak (0.2–0.4) and absent (0.0–0.2). Convergent 
validity was also tested for the total (or subscale) 
scores; we hypothesised that the LCADL would 
correlate with CRQ dyspnoea subscale, CRQ 
health-related quality of life (HRQL), HADS and 
NRS breathlessness on exertion. In addition, we 
hypothesised that there would be no correlation 
between the LCADL and lung function measures.
To investigate if diagnosis or presence of a carer influ-
enced LCADL scores, LCADL scores were compared 
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between the three main patient groups (COPD, interstitial 
lung disease (ILD) and cancer) and between patients with 
and without a carer present using Mann–Whitney U test. 
Data were analysed using the Statistical Package for Social 
Science for Windows, version 19 (SPSS Inc., Chicago, IL, 
USA). p < 0.05 was considered significant.
Data reporting
We searched http://www.equator-network.org/ for publish-
ing guideline for validation studies for health/symptom 
questionnaires. No publication guidelines were returned; 
therefore, we report our data in line with Terwee et al.’s18 
quality criteria for reporting measurement properties of 
health status questionnaires.
Results
A total of 105 patients were recruited to the main study;7 
with regard to this secondary data analysis, nine patients 
(COPD = 4, Cancer = 3, ILD = 2) were excluded due to 
incomplete or missing LCADL data.
Eight patients were excluded as they didn’t have a 
primary respiratory diagnosis (5 = heart failure) or they 
had an atypical/complex diagnosis (left lower lobe col-
lapse of unknown aetiology associated with severe 
symptoms; lupus, shrinking lung syndrome and rheuma-
toid arthritis; severe asthma and gastro-oesophageal 
reflux disease). A total of 88 patients were included in 
the data analysis for this article.
Table 1 summarises the participant demographics, pul-
monary function and NRS breathlessness scores. Individual 
item scores for the LCADL are summarised in Figure 1. In 
all, 11 (12.5%) patients reported little impact of their 
breathing on their normal ADLs; however, the majority of 
patients (77 (87.5%)) reported that their breathing impacted 
a lot on their normal ADLs.
Scaling assumptions
The median item score for the LCADL and subscales with 
the exception of the domestic subscale were around or 
above the midpoint (Table 2). The mean (95% confidence 
interval) inter-item correlation coefficient for single meas-
ures was 0.49 (0.43–0.55), p < 0.001.
Acceptability
LCADL total and subscales spanned a good range. No 
floor or ceiling effect was observed for the LCADL total 
score. However, the LCADL subcategory ‘domestic’ dem-
onstrated a ceiling effect, with 23% of respondents achiev-
ing the highest possible score (Table 2).
Internal consistency
Cronbach’s alpha for LCADL total score was 0.90 and 
for its subscales ranged between 0.50 and 0.91 
(Table 2).
Construct validity
Correlations between the LCADL and subscales were 
analysed according to 15 a priori hypotheses of conver-
gent (moderate to weak) and divergent validity. Of the 15 
hypotheses tested, 13 were correct (87%) (Table 3).
Table 1. Participant demographics, pulmonary function and NRS breathlessness scores.
Number/median Range (min–max)
Sex (n) 51 males, 37 females  
Age (years) 68 43–88
Diagnosis (n) COPD (53), ILD (17), cancera (18)  
Carer present Yes = 66 No = 22  
COPD = 39 COPD = 14  
ILD = 15 ILD = 2  
Cancer = 12 Cancer = 6  
NRS worst 24 h 6 0–10
NRS exertion 24 h 9 5–10
FEV1 (L) 0.9 0.30–3.7
FEV1 (% predicted) 38 12–106
VC (L) 4.7 0.40–5.1
VC (% predicted) 48 12–116
SaO2 (%) 95 77–98
NRS: numerical rating scale; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; FEV1: forced expiratory volume in 1 s; VC: 
vital capacity; SaO2: oxygen saturation.
a Primary cancer type; lung cancer = 12, metastatic breast cancer = 2, metastatic colon cancer = 1, metastatic prostate cancer = 1 and haematological 
(myeloma, lymphoma) = 2.
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Influence of diagnosis or presence of a carer on 
LCADL scores
The median (range) LCADL score for the COPD patients 
was 49 (17–67); for cancer patients, it was 44 (16–61) and 
for ILD patients 39 (14–59). A significant difference was 
observed for the self-care subcategory of the LCADL 
between the three patient groups (p = 0.018). Table 4 sum-
marises the LCADL total score and its subcategory scores 
for these three main patient groups.
No difference in LCADL total scores was observed 
between those patients who had a carer present and those 
without. However, a significant difference was observed 
for the self-care subcategory of the LCADL between 
patients with and without a carer (12 (4–20) vs 10 (4–12), 
p = 0.03) (Table 4).
Discussion
The psychometric analyses of the LCADL suggest that 
the instrument is acceptable, reliable and valid to assess 
the impact of RB on ADLs in patients with advanced 
disease.
Significance of the findings
To test the application of the LCADL in patients with 
advance disease and RB, we hypothesised that the LCADL 
would reflect other patient-reported measures of breath-
lessness, symptom burden and HRQL. There was a moder-
ate relationship between the LCADL, HRQL measured on 
the CRQ and its sub-domain dyspnoea. A finding consist-
ent with previous studies in COPD7,8 and heart failure20 
Figure 1. Individual item scores for the LCADL (n = 88).
Table 2. Psychometric properties of the London Chest Activity of Daily Living Scale (LCADL) (n = 88).
LCADL total 
(15 items)
LCADL self-care 
(4 items)
LCADL domestic 
(6 items)
LCADL physical 
(2 items)
LCADL leisure 
(3 items)
Missing data items (n items 
missing/n total items) (%)
0/1440(0) 0/384 (0) 0/576 (0) 0/192 (0) 0/288 (0)
Item possible score (range) 0–5 0–5 0–5 0–5 0–5
Total possible score (range) 0–70 0–20 0–30 0–10 0–15
Observed score range 14–67 4–20 0–30 2–9 2–11
Median score (range) 46.5 (14–67) 110 (4–20) 23 (0–30) 6 (2–9) 8 (2–11)
Floor effect (%) 0 0 4.5 0 0
Ceiling effect (%) 0 1 23 1 2
Cronbach’s alpha 0.90 0.87 0.91 0.50 0.62
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was that LCADL demonstrated good relationship with 
HRQL, functional status and exercise capacity.
A weak correlation between NRS breathlessness inten-
sity at rest and the LCADL was observed. This is not sur-
prising, as we have recently demonstrated that patients 
with chronic respiratory disease have a blunted perception 
of neural respiratory drive (NRD) and breathlessness at 
rest, where breathlessness onset/perception is associated 
with physical activity.21,22,25,26 Therefore, in the clinical 
context, if we only assess breathlessness intensity at rest, 
very important clinical information about the true impact 
of the patient’s condition is lost.
The observed weak relationship between NRS inten-
sity on exertion over the past 24 h and LCADL may be a 
consequence of patients avoiding ADLs that makes them 
breathless, resulting in NRS scores over the period of 
recall not being very high. Hence, the correlation between 
the functional consequence of breathlessness (impact 
measured using the LCADL score) and the NRS exertion 
(breathlessness intensity) is low. The advantage of the 
LCADL score over NRS breathlessness intensity scores 
is that it allows quantification of the functional limitation 
of breathlessness specific to the individual patients’ 
circumstance.
The LCADL was correlated to the CRQ dyspnoea 
domain, which rates breathlessness intensity during 
patient-defined activities. A limitation of the CRQ dysp-
noea domain is that it only provides a global measure of 
dyspnoea intensity during activity.13,14
In accordance with other studies,8,23 there was no statis-
tical correlation between pulmonary function measures 
and the LCADL. This supports the view that measures 
of lung function impairment are a poor prognostic of dis-
ability and do not reflect the burden of breathlessness 
Table 4. Total LCADL score and its subcategory scores categorised by diagnosis (COPD, ILD and cancer) and the presence of a 
carer.
COPD (n = 53), 
median (range)
Cancer (n = 18), 
median (range)
ILD (n = 17), 
median (range)
Carer present (n = 66), 
median (range)
No carer present 
(n = 22), median (range)
LCADL total score 49 (16–61) 44 (16–61) 39 (14–59) 49 (14–67) 42 (22–59)
LCADL self-care 12 (4–20)* 10.5 (4–14)* 8 (4–14)* 12 (4–20)* 9 (4–12)*
LCADL domestic 24 (0–46) 19.5 (0–30) 19 (0–30) 24 (0–30) 19 (6–30)
LCADL physical 6 (2–8) 5.5 (4–9) 6 (3–8) 6 (3–8) 6 (2–9)
LCADL leisure 8 (3–11) 7.5 (2–10) 8 (5–10) 8 (2–11) 8 (3–10)
LCADL: London Chest Activities of Daily Living Scale; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease.
To investigate if diagnosis or presence of a care influenced LCADL scores, LCADL scores were compared between the three main patient groups 
(COPD, ILD and cancer) and between patients with and without a carer present using Mann–Whitney U test.
*A significance difference p < 0.05.
Table 3. A priori hypothesis and results for construct validity using Spearman correlation coefficients of the LCADL and NRS 
breathlessness scores, CRQ, POS and POS–s, HAD and spirometry.
Hypothesis Comparison Spearman’s correlation (r) p
Moderate convergent validity expected 
between items. Expected correlation 
r = 0.4–0.7 (or negative if scales showed 
worsening/improvement in opposite 
direction)
LCADL total + NRS breathlessness at rest 0.25 0.03
LCADL total + NRS breathlessness on 
exertion (past 24 h)
0.24 ⩽0.001
LCADL total + CRQ HRQL −0.40 ⩽0.001
LCADL total + CRQ Dyspnoea −0.56 ⩽0.001
LCADL total + POS–s breathlessness 0.40 ⩽0.001
Weak convergent validity expected 
between items. Expected correlation 
r = 0.2–0.4 (or negative if scales showed 
worsening/improvement in opposite 
direction)
LCADL total + CRQ mastery −0.30 ⩽0.001
LCADL total + CRQ fatigue −0.31 ⩽0.001
LCADL total + POS total score 0.40 ⩽0.001
LCADL total + POS –s mobility 0.40 ⩽0.001
LCADL total + HAD depression −0.29 ⩽0.001
LCADL total + HAD anxiety 0.08 0.94
Divergent validity expected between 
items. Expected correlation r < 0.2 (or 
negative if scales showed worsening/
improvement in opposite direction) 
LCADL total + FEV1 %predicted −0.13 0.30
LCADL total + FVC %predicted −0.11 0.40
LCADL total + FEV1/VC −0.117 0.89
LCADL total + PEF −0.11 0.40
LCADL: London Chest Activities of Daily Living Scale; NRS: numerical rating scale; CRQ: Chronic Respiratory Questionnaire; POS: Palliative care 
Outcome Scale; POS-s: Palliative care Outcome Scale–symptoms; HAD: Hospital Anxiety and Depression; HRQL: health-related quality of life;  
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VC: vital capacity; PEF: peak expiratory flow. Correlations that were consistent 
with hypotheses are in bold.
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perceived by the patient, particularly when considering 
advanced disease.
Comparison between disease groups (COPD, ILD and 
cancer) showed that the median scores of LCADL were 
not significantly different, although there was a trend 
towards a higher score in COPD patients. However, the 
subcategory ‘self-care’ was significantly higher in COPD 
compared with the other condition-specific groups. The 
COPD population reported higher scores (12) than cancer 
(10.5) or ILD (8). This suggests that patients with COPD 
may benefit from assessment of functional breathlessness 
limitation early in the trajectory of their disease.
The self-care component of the LCADL provides infor-
mation about limitations in ADLs due to breathlessness. 
This component of the questionnaire is very focussed on 
personal hygiene activities such as washing, drying and 
dressing. Importantly, assessment of breathlessness limita-
tion on ADL may specifically facilitate discussion with 
regard to more focused palliative therapy, approach to 
symptom management rather than disease orientated treat-
ments, thus facilitating referral to therapy services.
Anxiety and depression are elevated in COPD24 and 
palliative care patients,21 and in this study, a correlation 
was observed between depression, the LCADL and its sub-
category leisure. In all, 45% of patients reported that they 
become very breathless going out socially, with 38% 
patients reporting that they were no longer able to go out 
socially due to their level of breathlessness as measured on 
the social participation question on the LCADL, reflective 
of the negative downward spiral that breathlessness has on 
activity of daily living, subsequent loss of muscle strength, 
function and ability to fully participate and engage within 
society.22 The LCADL may therefore be a useful tool to 
tease out issues concerning breathlessness in the context of 
activity and social role, which may facilitate discussion 
regarding the psychosocial impact of breathlessness and 
subsequent referral to physiotherapy and occupational 
therapy to improve social participation through interven-
tions such as mobility aids, pacing, breathlessness man-
agement, exercise and therapeutic group activities.
The LCADL subcategory self-care was significantly 
higher where carer support was available. An unusual aspect 
of the LCADL is that it asks specifically about activities an 
individual can still do (but is breathless) and activities they 
require assistance for or have had to give up. Higher scores 
indicate that the individual is more affected and where 
help is required or an activity has had to be given up. This is 
reflected by the observed ceiling effect for the subcategory 
domestic where 23% of respondents achieved the highest 
possible score. Although not tested in this study, the LCADL 
may be a useful tool to explore unmet needs with respect to 
social services support or occupational therapy input.
The majority of outcome scales and scores used to 
quantify breathlessness measure the intensity or the symp-
tom burden of breathlessness, but fail to measure the 
impact of the symptom on ADLs.
Comprehensive assessment of patients’ supportive 
needs in advanced disease requires sensitive questioning, 
inclusion of questions regarding breathlessness specifically 
in the context of ADLs. Potentially using the LCADL in the 
clinical assessment of patients with RB may aid these dis-
cussions and highlight patients who may not traditionally 
be considered for physiotherapy or occupational therapy, 
thus facilitating access to these specialist services.
Critique of the method
When interpreting these results, some limitations need to 
be acknowledged. We are unable to make comment on the 
discriminative ability of the LCADL from our current data 
set, and future studies could include performance status 
measures such as the World Health Organization (WHO) 
Performance status and Karnofsky which may provide 
useful comparators.
We did not conduct test–retest analysis on this data set, 
so the reliability of this tool over time in this patient popu-
lation remains unknown. The LCADL control group data 
at 6 weeks are inappropriate for test–retest data because 
many patients were in the progressive phase of their dis-
ease. In the context of this patient population, a 6-week 
test–retest window does not reflect a stable state. Our rea-
soning is reinforced by the fact that the drop out due to 
illness or death was quite high in our control group.
Conclusion
Psychometric analyses suggest that the LCADL is accept-
able, reliable and valid in patients with advanced disease 
and RB. The LCADL may highlight previously unreported 
areas of need with respect to breathlessness during ADLs 
and the extent of social support required which may facili-
tate access to services such as physiotherapy and occupa-
tional therapy.
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